130922-40-6

Basic information

• Product Name: Benzene, 2,4-difluoro-1-(methylthio)- (9CI)
• Synonyms: Benzene, 2,4-difluoro-1-(methylthio)- (9CI);2,4-Difluoro-1-(methylthio)benzene;2,4-Difluoro-1-(methylsulfanyl)benzene
• CAS NO: 130922-40-6
• Molecular Formula: C₇H₆F₂S
• Molecular Weight: 160.1843464
• Product Categories: HALIDE
• Mol File: 130922-40-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 164°Cat760mmHg
• Flash Point: 53°C
• Appearance: /
• Density: 1.23g/cm³
• Vapor Pressure: 2.63mmHg at 25°C
• Refractive Index: 1.521
• CAS DataBase Reference: Benzene, 2,4-difluoro-1-(methylthio)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 2,4-difluoro-1-(methylthio)- (9CI)(130922-40-6)
• EPA Substance Registry System: Benzene, 2,4-difluoro-1-(methylthio)- (9CI)(130922-40-6)

Safety Data

• Hazardous Substances Data: 130922-40-6(Hazardous Substances Data)

Usage

General Description

Benzene, 2,4-difluoro-1-(methylthio)- (9CI) is a chemical compound with the molecular formula C7H6F2S. It is a colorless, flammable liquid with a strong odor. This chemical is commonly used in the production of pharmaceuticals, pesticides, and other organic compounds. Its primary use is as an intermediate and raw material in the synthesis of various chemical products. However, it is important to note that Benzene, 2,4-difluoro-1-(methylthio)- (9CI) is considered to be hazardous, and exposure to this chemical can cause harmful effects on human health and the environment. Therefore, strict safety measures and proper handling protocols should be followed when working with this compound.

InChI:InChI=1/C7H6F2S/c1-10-7-3-2-5(8)4-6(7)9/h2-4H,1H3

Upstream product

• 1996-44-7 2,4-difluorothiophenol 
• 74-88-4 methyl iodide 

Downstream Products

• 1535177-80-0 2,4-difluoro-3-iodothioanisole 
• 236739-02-9 2,4-difluoro-1-(methylsulfonyl)benzene 
• 66623-75-4 Methylmercapto-3-fluoranisol 
• 5633-61-4 2,4-dimethoxy-1-(methylsulfanyl)benzene 
• 1173006-35-3 C₈H₉FOS 

Relevant articles and documents

COMPOUNDS

The present invention relates to a compound of formula (Ia), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H, Cl and F; R5 is selected from H, alkyl, alkynyl, alkenyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, Cl, F, SO2-alkyl, SO2NR13R14, optionally substituted heteroaryl and alkyl; R8 is selected from H, alkyl, haloalkyl and halo; R9 is H, C1-C3-alkyl, or halo; R10 and R11, together with the nitrogen to which they are attached, form an azepanyl group, wherein (a) said azepanyl group is substituted by one or more substituents, or (b) one or two carbons in said azepanyl group are replaced by a group selected from O, NH, S and CO, and said azepanyl group is optionally further substituted; or R10 and R11, together with the nitrogen to which they are attached, form an azetidinyl, pyrrolidinyl or piperidinyl group wherein (a) said azetidinyl, pyrrolidinyl or piperidinyl group is substituted by one or more substituents, or (b) one or two carbons in said azetidinyl, pyrrolidinyl or piperidinyl group are replaced by a group selected from NH, S and CO; or R10 and R11, together with the nitrogen to which they are attached, form an 8, 9 or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced by a group selected from O, NH, S and CO, and said bicyclic heterocycloalkyl group is optionally substituted; or R10 and R11, together with the nitrogen to which they are attached, form a 6 to 12-membered bicyclic group containing a spirocyclic carbon atom, wherein one or two carbons in the bicyclic group are optionally replaced by a group selected from O, NH, S and CO, and said bicyclic group is optionally substituted, or said bicyclic group is optionally fused to a 5 or 6-membered aryl or heteroaryl group; R13 and R14 are each independently H or alkyl. Further aspects of the invention relate to such compounds for use in the field of immune-oncology and related applications.